JPRN-UMIN000051060招募中2 期
ab-Paclitaxel plus trastuzumab and pertuzumab as a neoadjuvant chemotherapy for low-risk HER2-positive breast cancer - PerSeUS-BC06
Gifu University Graduate School of Medicine Breast Surgery0 个研究点目标入组 35 人开始时间: 2023年5月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Inflammatory and/or bilateral breast cancer 2)Duplicated/sunchromus/metachromus cancer(DFS less than 5y) 3)Severe complication (cardiovascular, lung, liver disease, homorragic ulcer etc.) 4)febrile, susupicious for infection 5)Interstitial pneumonia or pulmonary fibrosis by chest-X/CT 6)Active systhemic infevtion (HBV, HCV, HIV etc.) 7)Uncontrollable pheripheral pneuropathy due to DM, V-12 deficiency etc. 8)Severe allergy to drug 9)Pregnancy, Lactation 10)Uncontrollable mental disease 11)Not suitable for this study judged by physician/Surgeon
研究者
相似试验
招募中
2 期
ab-Paclitaxel plus trastuzumab and pertuzumab followed by EC as a neoadjuvant chemotherapy for HER2-positive operable breast cancerBreast CancerJPRN-UMIN000035235Gifu University Graduate School of Medicine Department of Surgical Oncology30
进行中（未招募）
1 期
Pembrolizumab and trastuzumab in combination with chemotherapy before and after surgery for patients with HER2-positive gastric cancer - PHERFLOT –HER2 positive, localized esophagogastric adenocarcinomaMedDRA version: 20.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10066896Term: HER2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-006512-87-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH30
进行中（未招募）
1 期
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant (before surgery) treatment of HER2 positive early high-risk and locally advanced breast cancer.Women with a diagnosis of non-metastatic high-risk invasive unilateral, HER2-positive breast cancer.MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000981-31-BEFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI650
进行中（未招募）
1 期
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant (before surgery) treatment of HER2 positive early high-risk and locally advanced breast cancer.EUCTR2017-000981-31-ATFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI650
进行中（未招募）
1 期
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant (before surgery) treatment of HER2 positive early high-risk and locally advanced breast cancerWomen with a diagnosis of non metastatic high-risk invasive unilateral, HER2-positive breast cancerMedDRA version: 20.0Level: LLTClassification code 10006283Term: Breast neoplasm malignant femaleSystem Organ Class: 100000004864EUCTR2017-000981-31-ITFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI650